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The choroid plexus epithelium (CPE) secretes higher volumes of fluid (CSF) than any other 31 
epithelium and simultaneously functions as the blood-CSF barrier to gate immune cell 32 
entry into the CNS.1 Post-hemorrhagic hydrocephalus (PHH), an expansion of the cerebral 33 
ventricles due to CSF accumulation following intraventricular hemorrhage (IVH), is a 34 
common disease usually treated by suboptimal CSF shunting techniques.2 PHH is 35 
classically attributed to primary impairments in CSF reabsorption, but little experimental 36 
evidence supports this concept. In contrast, the potential contribution of CSF secretion to 37 
PHH has received little attention. We demonstrate here that IVH causes a toll-like 38 
receptor-4 (TLR4) and NF-κB-dependent inflammatory response of the CPE that is 39 
associated with a ~3-fold increase in bumetanide-sensitive CSF secretion. IVH-induced 40 
CSF hypersecretion is mediated by the TLR4-dependent activation of the Ste20-type stress 41 
kinase SPAK, which binds, phosphorylates, and stimulates the NKCC1 cotransporter at 42 
the CPE apical membrane. Genetic depletion of TLR4 or SPAK normalizes hyperactive 43 
CSF secretion rates and reduces PHH, as does treatment with drugs that antagonize TLR4-44 
NF-κB signaling or the SPAK-NKCC1 cotransporter complex. These data uncover a 45 
previously unrecognized contribution of CSF hypersecretion to the pathogenesis of PHH, 46 
demonstrate a novel role for TLRs in regulation of the internal brain milieu, and identify a 47 
kinase-regulated mechanism of CSF secretion that could be targeted by repurposed, FDA-48 
approved drugs to treat hydrocephalus.  49 
 50 
IVH frequently leads to PHH, worsening outcomes of germinal matrix and subarachnoid bleeds, 51 
and of intraparenchymal hemorrhage.2 The elevated intracranial pressure (ICP) in PHH damages 52 
periventricular white matter, impairing brain development in children and causing 53 
neurodegeneration in adults.3 Severe, persistent elevations in ICP can cause acute brainstem 54 
herniation and death. The mainstay of PHH treatment remains invasive CSF shunting, an empiric 55 
“one-size-fits-all” approach with high morbidity due to frequent shunt obstructions and 56 
infections requiring surgical revision.2 Targeted pharmacotherapeutic strategies constitute an 57 
urgent unmet need for hydrocephalus patients of all ages.3 58 
 59 
It is widely accepted that PHH results from intraventricular CSF accumulation due to failed 60 
homeostasis mechanisms. Classic models of CSF dynamics hold that PHH results from a primary 61 
decrease in CSF reabsorption due to intraventricular CSF flow obstruction and/or dysfunction of 62 
extraventricular arachnoid granulations; however, this paradigm is supported by sparse 63 
experimental evidence,4 and neglects potential roles of increased CSF secretion in disease 64 
pathogenesis.5 Although intracerebroventricular (ICV) injection of IVH-derived metabolites is 65 
sufficient to cause CPE inflammation,6 and hydrocephalus,7 the molecular mechanisms by which 66 
IVH leads to ventriculomegaly remain incompletely understood.  67 
 68 
Systemic secretory epithelia can respond to pro-inflammatory stimuli by increasing their rate of 69 
fluid secretion.8 Initially, this secretory response may be adaptive in maintaining homeostasis by 70 
clearing pathogenic organisms or debris from the epithelial surface.9,10 However, sustained 71 
inflammation can be maladaptive and create disease vulnerabilities,11,12 and dysregulated 72 
epithelial homeostasis can manifest  result in chemical (sterile), autoimmune, and infectious 73 
pleuritis, colitis, pancreatitis, and other conditions.13,14 Interestingly, CSF hypersecretion due to 74 
CPE hyperplasia or choroid plexus tumors is sufficient to cause non-obstructive hydrocephalus;5 75 
however, the impact of IVH on CSF secretion from the CPE has not been studied.   76 
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 77 
We hypothesized that IVH-induced CPE inflammation might contribute to the development of 78 
PHH by increasing the rate of CSF secretion from the CPE. To test this hypothesis, we first 79 
assessed CPE inflammation after the experimental simulation of IVH in an established rat model 80 
of PHH,15 induced by intracerebroventricular injection of sterile, LPS-free, autologous blood in 81 
8-week-old, male Wistar rats. Control rats received ICV injection of sterile artificial CSF for 82 
comparision.15 Experimental PHH rats developed ventriculomegaly 48 hours after ICV injection 83 
and CPE cells harbored significant activation of NF-κB signaling, as demonstrated by elevated 84 
nuclear translocation of p65, a subunit of the NF-κB-p65 transcription complex (Suppl Fig 1). 85 
This was accompanied by increased numbers of activated ED1+ (CD68) choroid plexus myeloid 86 
cells15 compared to control rats (Suppl Fig 1 A, B). Intraperitoneal (IP) delivery of the NF-κB 87 
inhibitor ammonium pyrrolidinedithiocarbamate (PDTC)16 lowered IVH-associated increases in 88 
p65 nuclear translocation and ED1+ cells (Suppl Fig 1 C). IHC analysis of CPE showed 89 
increased expression of NF-κB-p65 and the NF-κB-dependent proteins, TNFα and CD68 (as 90 
indicated by ED1), in IVH rats compared to controls at 48h and at 7 days (Suppl Fig 2). 91 
Consistent with previous reports,6,15 these results demonstrate that IVH triggers CPE 92 
inflammation dependent on NF-κB activation.  93 
 94 
We next evaluated the effect of IVH on the CSF secretion rate from the lateral ventricle CPE 95 
using a recently developed direct method of measurement in live rats (Fig 1 A).17 This method 96 
blocks CSF exit from the third ventricle at the level of the Sylvian aqueduct with mineral oil (Fig 97 
1 A). These conditions prevent contributions to measured CSF production via CSF reabsorption 98 
pathways distal to this block, including glymphatic pathways or arachnoid granulations near the 99 
superior sagittal sinus. Therefore, this technique measures bona fide lateral ventricle CSF 100 
production (LVCP) by the CPE, as demonstrated previously.17 48 hours after ICV injection of 101 
blood, LVCP was ~1.40 ± 0.07 μL/min, nearly 3-fold greater than that of either naïve rats or 102 
sham-operated controls (~0.50 ± 0.05 μL/min; Fig 1 B; p < 0.01). LVCP peaked at 24h post-IVH 103 
and remained elevated at 7 days (Fig 1 B). This increase in LVCP was associated with 104 
significant ventriculomegaly (Fig 1 C, D; ~2.45 ± 0.05 mm3 in controls versus ~5.40 ± 0.70 mm3 105 
in IVH; p < 0.01). Infusion of artificial CSF (aCSF) into the lateral ventricles of naïve rats at a 106 
rate of 1 μL/min for 8 hours, approximating the difference in LVCP between IVH and control 107 
rats (see Fig 1 C, D), recapitulated the ventriculomegaly seen after IVH (Fig 1 C, D; ~4.90 ± 108 
0.40 mm3; p < 0.05 compared to controls; p > 0.05 compared to IVH). These data show IVH 109 
causes a significant increase in CSF secretion that is sufficient to cause acute PHH. 110 
 111 
Ion and water transport molecules expressed on the apical and basolateral membranes of the CPE 112 
mediate CSF secretion via the vectorial transport of Na+, Cl-, and HCO3- from blood into the 113 
ventricles, accompanied by K+ recycling across the apical CPE membrane.18 We investigated the 114 
molecular determinants of IVH-induced CSF hypersecretion. ICV delivery of acetazolamide to 115 
inhibit carbonic anhydrase (CA) isoforms that regenerate HCO3- only mildly lowered IVH-116 
induced CSF hypersecretion (Fig 1 E). Systemic administration of PDTC to inhibit NF-κB 117 
decreased CSF hypersecretion and ventriculomegaly after IVH (Fig 1 E; CSF: ~45% reduction, p 118 
< 0.01; Fig 2 G; ventriculomegaly: ~55% decrease, p < 0.01).  ICV (but not systemic) delivery of 119 
bumetanide, an inhibitor of cation-Cl--cotransporter NKCC1, significantly reduced post-IVH 120 
CSF hypersecretion and ventriculomegaly (Fig 1 F-G; CSF: ~80% reduction at 48h and ~70% 121 
reduction at 7 days; p < 0.01; Fig 1 G; ventriculomegaly: ~50% reduction, p < 0.01). These 122 
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results demonstrate that CSF hypersecretion after IVH is sensitive to inhibitors of inflammation 123 
(PDTC) and NKCC1-dependent ion transport.  124 
 125 
We evaluated the expression of specific CPE ion transporter polypeptides in the presence or 126 
absence of IVH using Western blotting of CPE homogenates fractionated by SDS-PAGE. IVH 127 
significantly increased the functional expression of NKCC1, detected as "pNKCC1" (the active, 128 
ion-transporting species phosphorylated at residues P-Thr203/P-Thr207/P-Thr212)19 (Fig 2 A, B; 129 
~6.8-fold activation, p < 0.01). In contrast, protein expression of AQP1 and the Na+/K+ ATPase 130 
(including Na+/K+ ATPase P-Ser23) were mildly decreased (p < 0.05) in the setting of IVH (Fig 2 131 
A, B).  132 
 133 
In other cell types, the conserved C-terminal domain (CCT) of the serine-threonine 134 
STE20/SPS1-related, proline alanine-rich kinase (SPAK) associates with the (R/K)FX(V/I) motif 135 
of NKCC1 and phosphorylates its N-terminus at Thr203, Thr207, and Thr212.20 Like other Ste20-136 
type kinases that serve as MAP4Ks, SPAK integrates and transduces environmental stress,20 137 
including NF-κB-dependent inflammatory signals.21,22 Given the IVH-induced increase in both 138 
NKCC1 P-Thr203/P-Thr207/P-Thr212 and bumetanide-sensitive CSF secretion, we tested the effect 139 
of IVH on SPAK expression using total and phospho-specific antibodies on CPE homogenates 140 
(Fig 2 A, B). Similar to NKCC1, IVH significantly increased the functional expression of SPAK 141 
(SPAK P-Ser373 “pSPAK”) > 2-fold (p < 0.01) relative to that in control animals (Fig 2 A, B).  142 
 143 
Reciprocal co-immunoprecipitation experiments from CPE homogenates using total and 144 
phospho-specific anti-SPAK antibodies and anti-NKCC1 antibodies each showed that SPAK and 145 
NKCC1 form a physical complex in the CPE (Fig 2 C). This complex includes the 146 
phosphorylated and active species of each (pSPAK and pNKCC1) (Fig 2 C, D). The interaction 147 
between pSPAK and pNKCC1 was increased in the setting of IVH (Fig 2 C, D). Consistent with 148 
our Western and co-immunoprecipitation results, immunohistochemistry on CPE sections 149 
labeled with anti-pSPAK and anti-pNKCC1 antibodies showed a significant increase in pSPAK 150 
and pNKCC1 at the apical membrane of the CPE after IVH (Fig 2 E, F). Treatment with the NF-151 
κB inhibitor PDTC blocked the IVH-dependent up-regulation of pSPAK-pNKCC1 after IVH 152 
(Fig 2 E, F).  153 
 154 
We applied pharmacological and genetic approaches to test the functional contribution of 155 
pSPAK-pNKCC1 to development of PHH. ICV administration of STOCK1S-50699, which 156 
disrupts binding between SPAK and NKCC1,23 restored CSF secretion rates after IVH to basal 157 
levels (Fig 2 G; CSF: ~50%; p < 0.01). Closantel, which directly inhibits SPAK kinase activity,24 158 
restored CSF secretion rates to basal levels and normalized ventricular size after IVH (Fig 2 G; 159 
CSF: ~65%; p < 0.01; Fig 2 H, I; ventriculomegaly: ~40%, p < 0.05). STOCK1S-50699 and 160 
closantel were administered either ICV at the time of CSF measurement or ICV via osmatic 161 
pump at the time of IVH for ventriculomegaly analysis (see Methods). ICV delivery of SPAK 162 
antisense oligodeoxyribonucleotides (AS-ODNs), but not scrambled control ODNs (Scr-ODNs; 163 
see Methods), decreased levels of both SPAK and pNKCC1 (Suppl Fig 3), and attenuated IVH-164 
induced CSF hypersecretion (Fig 2 G; ~45%; p < 0.01). These data show that chemical or 165 
genetic inhibition of SPAK-NKCC1 complex decreases IVH-induced CSF hypersecretion and 166 
ventriculomegaly. 167 
 168 
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We next explored the upstream mechanisms that mediate CPE inflammation and pSPAK-169 
pNKCC1 up-regulation after IVH. Toll-like receptor-4 (TLR4)-/NF-κB signaling is a critical 170 
mediator of the innate immune response to bacteria-derived lipopolysaccharide (LPS),25 but is 171 
also activated by other host-derived “alarmins” or damage-associated molecular patterns 172 
(DAMPs), including sterile blood metabolites.26 TLR4 is expressed in CPE cells,27 but the role 173 
for TLR in the pathogenesis of PHH is unclear. We tested the effect of TLR4 inhibition on IVH-174 
induced up-regulation of pSPAK-pNKCC1 using the specific TLR4 inhibitor, Tak24228 (Fig 3 A, 175 
E) and TLR4 KO rats (Fig 3 B, F).  176 
 177 
IVH activated TLR4 signaling, as evidenced by up-regulation of TAK1 p-Thr187 (~2-fold, p < 178 
0.05), NF-κB-p65 (up to 9-fold, p < 0.05), and pNF-κB-p65 (p-Ser536) (> 90-fold, p < 0.05) at 179 
24h and 48h post-IVH, and to a lesser extent at 7 days post-IVH (Fig 3 A, B). These changes 180 
were accompanied by increased pSPAK (~2-fold, p < 0.01) and pNKCC1 (~6-fold, p < 0.01) 181 
(Fig 3A, C). Tak242 abrogated the IVH-induced activation of TLR4 signaling and the activating 182 
phosphorylation of both pSPAK (p < 0.01) and pNKCC1 (p < 0.01) (Fig 3 A, E). TLR4 KO also 183 
abolished the IVH-induced activation of TLR4 signaling and the up-regulation of pSPAK (p < 184 
0.01) and pNKCC1 (p < 0.01) (Fig 3 B, F). In contrast, expression of the Na+/K+ ATPase and 185 
AQP1 was mildly decreased at 24h post-IVH, and restored 7 days post-IVH (p < 0.05).  186 
 187 
We next assessed the role of TLR4 inhibition on IVH-induced CSF hypersecretion using Tak242 188 
or TLR4 KO rats (Fig 3 G). In contrast to the increased rates of CSF secretion measured in TLR4 189 
WT rats in response to IVH, CSF secretion rates in TLR4 KO rats were not significantly 190 
different from those in control animals (Fig 3 G; CSF: ~70% reduction, p < 0.01). Consistent 191 
with this, Tak242 also decreased CSF hypersecretion at 48h post-IVH (Fig 3 G; CSF: ~53% 192 
reduction, p < 0.01). These data demonstrate TLR4 is required for IVH-induced CSF 193 
hypersecretion associated with CPE inflammation. 194 
 195 
The data presented here offer several novel insights (Suppl Fig. 4). First, IVH triggers CSF 196 
hypersecretion by the CPE, uncovering a previously unrecognized contribution of increased CSF 197 
secretion to the pathogenesis of PHH. Second, IVH-induced CPE inflammation and CSF 198 
hypersecretion is dependent on TLR4-NFκB signaling, demonstrating a novel role for TLRs in 199 
the regulation of the internal brain milieu. Third, TLR4-NFκB stimulates CSF hypersecretion via 200 
the SPAK-NKCC1 cotransporter complex, identifying a novel kinase-regulated mechanism of 201 
CSF secretion.  202 
  203 
SPAK kinase is a master regulator of epithelial ion transporters and channels,20 including the 204 
cation-Cl- cotransporters29. In the nervous system, SPAK is most highly expressed in the CPE, 205 
where it localizes to the apical CPE membrane.30 We showed that SPAK and NKCC1 form a 206 
complex in the CPE, and that the phosphorylated, active species of each is increased after IVH. 207 
SPAK loss-of-function in the distal nephron results in low blood pressure from epithelial NaCl 208 
wasting31 due to decreased phosphorylation of the furosemide-sensitive NKCC2, a renal-specific 209 
NKCC1 homologue. We have shown the opposite phenomenon in PHH. After IVH, SPAK gain-210 
of-function in the CPE results in PHH from CSF hypersecretion due to increased 211 
phosphorylation of the bumetanide-sensitive NKCC1 at Thr residues homologous to those in 212 
NKCC2. These findings are consistent with the homology of ion transporters and their regulatory 213 
networks in the CPE and nephron.18 Elucidation of other ion and water transporters and their 214 
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regulators that coordinate with NKCC1 to mediate the CSF hypersecretory response could 215 
identify other therapeutic targets. 216 
 217 
SPAK-NKCC1-mediated CSF hypersecretion is dependent on TLR4/NF-κB signaling. SPAK is 218 
a signal transducer of environmental and cellular stress,20 including NF-κB-dependent 219 
inflammation.21,22 IFN-γ32 and TNF-α22 stimulate SPAK signaling in an NF-κB-dependent 220 
manner to increase epithelial transport in experimental colitis.32 SPAK could therefore be well 221 
positioned to mediate a TLR4/NF-κB-dependent epithelial “pro-secretory response” to 222 
inflammation. While CSF hypersecretion from the CPE after IVH may resemble the 223 
hypersecretory phenotype in other inflamed epithelia,13,14 it is poorly tolerated given the 224 
ventricular system’s confinement within the rigid skull, where even small elevations in CSF 225 
volume can create fatal increases in intracranial pressure.  226 
 227 
TLR4 inhibition decreases inflammatory injury and neurological deficits after intraparenchymal 228 
hemorrhage,33 and TLR4 and its downstream pathway components (NF-κB, and the NF-κB-229 
dependent cytokines TNFα and IL-1β) are up-regulated in the CPE after IVH.6 It has been 230 
reported that IVH-derived metabolites, such as heme33 and methemoglobin,34 serve as DAMPs to 231 
bind and activate TLR4. Our results corroborate these findings, and further suggest that specific 232 
IVH-derived metabolites may serve as CSF-borne host-derived DAMPs that induce TLR4/NF-233 
κB signaling in the CPE. These findings suggest post-infectious hydrocephalus (PIH), a 234 
devastating complication of meningitis from LPS-producing bacteria, could result from similar 235 
TLR4-dependent CSF hypersecretory mechanisms. Such a mechanistic similarity could be of 236 
great importance, since PIH is the most common type of hydrocephalus worldwide (including the 237 
developing world, where neurosurgeons are scarce and the costs of VP shunting are 238 
prohibitive).35 Future study into the normal and pathophysiological roles of TLRs in the CPE 239 
will be important topics of investigation.   240 
 241 
Previous trials failed to show efficacy of systemically administered furosemide or acetazolamide 242 
for the treatment of PHH associated with neonatal germinal matrix hemorrhage.36 However, 243 
furosemide and bumetanide have poor blood-brain barrier (BBB) penetration, and furosemide 244 
has significantly lower affinity for NKCC1 than bumetanide.37 ICV38 but not intraperitoneal,39 245 
delivery of the NKCC1 blocker bumetanide moderately decreases baseline CSF secretion in 246 
dogs, but bumetanide has not been studied in the context of PHH. We showed IVH-induced CSF 247 
hypersecretion and hydrocephalus is sensitive to ICV but not systemic bumetanide. This is 248 
consistent with the low BBB permeability of bumetanide37 and the post-IVH increase in 249 
pNKCC1 at the apical CPE membrane.  250 
 251 
Importantly, patients with PHH often require acute placement of temporary external ventricular 252 
drains or reservoirs to divert CSF and decrease elevated intracranial pressures before placement 253 
of a permanent in-dwelling VP-shunt several weeks later. Although endoscopic cauterization of 254 
the CPE has proven effective in some forms of infantile hydrocephalus,40 that efficacy may come 255 
at the expense of other critical and increasingly recognized functions of the CPE such as immune 256 
surveillance, growth factor production, and vitamin homeostasis.1 In contrast, acute ICV delivery 257 
of repurposed drugs targeting either TLR4-NF-κB-dependent inflammation or the SPAK-258 
NKCC1 complex might serve as a novel strategy to avoid permanent shunt dependence while 259 
preserving other critical “non-secretory” CPE functions.  260 
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FIGURE LEGENDS 279 
 280 
FIGURE 1. Intraventricular hemorrhage (IVH) triggers inflammation-dependent and 281 
bumetanide-sensitive cerebrospinal fluid (CSF) hypersecretion by the choroid plexus epithelium 282 
(CPE). 283 
 284 
(A) Left panel shows a schematic of the method of in vivo quantification of CSF secretion in a 285 
live rat model of post-hemorrhagic hydrocephalus. Yellow depicts a catheter injecting mineral 286 
oil into the fourth ventricle and cerebral aqueduct, causing an obstruction to CSF flow. 17 Blue 287 
represents a capillary tube inserted into the lateral ventricle proximal to this site of oil block that 288 
collects CSF secreted from the lateral ventricle CPE. Right upper panel shows stereotactic 289 
injection of into the lateral ventricle through a small parietal craniotomy. Right lower panel 290 
shows the direct measurement of CSF secretion in a live Wistar rat. Left arrow highlights the 291 
catheter used for mineral oil delivery; right arrow highlights the capillary tube and ruler used for 292 
quantitation of CSF secretion. 293 
(B) CSF secretion rates in control rats (CTL, n = 12) and in rats 24hr (n = 3), 48hr (n = 13), 72hr 294 
(n = 3) and 7 days (d) (n = 3) after IVH. Bars represent mean ± SEM of the rate of CSF secretion 295 
(μL/min). Symbols indicate data obtained from an individual animal. *, p < 0.05 vs. control rats 296 
(CTL), one-way ANOVA. 297 
(C) Representative photomicrographs of coronal sections of rat brains (at -0.6 mm from Bregma) 298 
that depict ventricular volume under various experimental conditions. N = naïve; CTL = vehicle 299 
injection; IVH = 48 hr post-experimental IVH; aCSF = 8 hr after a 1 μL/min infusion of artificial 300 
CSF to approximate the difference in CSF secretion at 48 hr post-IVH. Note the similarity of 301 
ventricular size after aCSF injection or IVH. Scale bar = 3.5 mm. 302 
(D) Graph depicting the mean ± SEM of lateral ventricle volume (mm3) in naïve rats (N, n=3), in 303 
control rats (CTL) which received vehicle injection only (n = 3), in rats 48 hours after IVH (IVH, 304 
n = 3), and in rats 8 hours after a 1μL/min infusion of artificial CSF (aCSF) (n = 5). *, p < 0.01 305 
vs control; #, p < 0.05 vs control but not vs. IVH (p > 0.05); one-way ANOVA.  306 
(E) Effect of intracerebroventricular (ICV) administration of the carbonic anhydrase inhibitor 307 
acetazolamide (ACZ), the NKCC1 cotransporter inhibitor bumetanide (BUM), and 308 
intraperitoneal (IP) administration of the NF-kB inhibitor Ammonium 309 
pyrrolidinedithiocarbamate (PDTC) on the rate of CSF secretion 48 hours post-experimental 310 
IVH. The graph represents the mean ± SEM (n=3) of the rate of CSF secretion (μL/min). *, p < 311 
0.01 vs. control (CTL); #, p < 0.01 vs. IVH but not vs. controls (p > 0.05); one-way ANOVA). 312 
Veh = ICV injection of vehicle.  313 
(F) Effect of intravenous (IV) injection of BUM 48 hours after experimental IVH. Note the 314 
absence of significant CSF secretion change after systemic administration of BUM, but not after 315 
ICV administration. 316 
(G) Effect of ICV administration of BUM in rats 48 hours and 7 days after experimental IVH. 317 
The graphs represent the mean ± SEM (n=3) of rates of CSF secretion (μL/min). *, p< 0.05 vs. 318 
minus BUM; paired t-test.  319 
 320 
 321 
FIGURE 2. CSF hypersecretion after IVH is dependent on the inflammation-induced phospho-322 
activation of the SPAK-NKCC1 complex in the CPE. 323 
 324 
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(A) Western Blot analysis of CPE ion transporters in control rats and rats 48 hours after 325 
experimental IVH. CPE lysates (n=3) were harvested and subjected to SDS-PAGE and to 326 
immunoblot with the indicated antibodies. Molecular mass is indicated in kDa. The blots in the 327 
figure have been cropped for presentation, please see supplemental information to view the 328 
uncropped blots. CTL = control rats; IVH = 48 hours post-experimental IVH. pSPAK = 329 
phosphorylated (active) SPAK; pOSR1= phosphorylated (active) OSR1 kinase; pNKCC1 = 330 
phosphorylated (active) NKCC1. AQP1 = aquaporin-1. 331 
(B) Graphs representing the β-Actin-normalized Western blot signal from panel (A) (mean ± 332 
SEM), as quantified in Methods. *, p < 0.05 vs. control; one-way ANOVA.  CTL = control rats; 333 
IVH= 48 hours post-experimental IVH. 334 
(C) Reciprocal co-immunoprecipitation of CPE lysates with anti-pSPAK and anti-pNKCC1 335 
antibodies. Upper panel: immunoblot against total NKCC1 and SPAK. Bottom panel: 336 
immunoblot against pNKCC1 and pSPAK. The blots in the figure have been cropped for 337 
presentation, please see supplemental information to view the uncropped blots. Molecular mass 338 
is indicated in kDa.  339 
(D) Reciprocal co-immunoprecipitation experiments with anti-SPAK and anti-NKCC1 specific 340 
antibodies in the CPE. Lysates from CPE were prepared (n=3) and subjected to 341 
immunoprecipitation (IP) and immunoblot (IB) after SDS-PAGE with the indicated antibodies. 342 
The blots in the figure have been cropped for presentation, please see supplemental information 343 
to view the uncropped blots.  Molecular mass is indicated in kDa. 344 
(E) Representative fluorescent photomicrographs immunolabeled for pSPAK (green) and 345 
pNKCC1 (red) using phospho-specific antibodies that detect the activated, phosphorylated 346 
species of each molecule in the CPE of rats 48 hours after treatment with vehicle control (CTL) 347 
or experimental IVH in the presence or absence of the NF-κB inhibitor PDTC. DAPI staining 348 
shown in blue. Scale bar = 200 μm. 349 
(F) Graphs depicting the mean ± SEM of the fluorescence quantification (ROI%) (see Methods) 350 
from fluorescent photomicrographs immunolabeled for pSPAK (upper panel) and pNKCC1 351 
(lower panel) as in (E) *, p < 0.01 vs. control; #, p < 0.05 vs. IVH but not vs. control (p > 0.05); 352 
one-way ANOVA. 353 
(G) Effect of genetic or pharmacologic inhibition of SPAK on IVH-induced CSF hypersecretion 354 
from the CPE. The graph represents mean ± SEM of the rate of CSF secretion (µL/min). *, p < 355 
0.01 vs. control; #, p < 0.01 vs. IVH but not vs. controls (p > 0.05); one-way ANOVA. ODN= 356 
oligodeoxyribonucleotide; Scr=Scrambled; AS=Anti-sense; Veh = Vehicle injection; STK = 357 
STOCK 1S-50699; Clos = Closantel. 358 
(H) Representative photomicrographs of coronal sections of brains (at -0.6 mm from Bregma) 359 
(left panel) from vehicle control rats (CTL) or in rats 48 hours after experimental IVH in the 360 
presence of ICV-delivered drugs. Scale bar = 3.5 mm.  361 
(I) Graph depicting the mean ± SEM of lateral ventricular volume (mm3) from rats as indicated 362 
in (H). *, p < 0.01 vs. control; #, p < 0.01 vs. IVH but not vs. control (p > 0.05); one-way 363 
ANOVA. 364 
 365 
 366 
FIGURE 3. TLR4-NF-κB signaling is required for the IVH-induced increase in SPAK-NKCC1-367 
dependent CSF hypersecretion. 368 
(A) Western Blot analysis of CPE ion mediators in control rats and rats 24 hr, 48 hr, and 7d after 369 
experimental IVH in the presence or absence of Tak242 (n=3). CPE lysates were harvested and 370 
 
 
10 
 
subjected to immunoblot with the indicated antibodies. The blots in the figure have been cropped 371 
for presentation, please see supplemental information to view the uncropped blots.  Molecular 372 
mass is indicated in kDa. CTL = control rats; IVH = post-experimental IVH. pSPAK = 373 
phosphorylated (active) SPAK; pOSR1= phosphorylated (active) OSR1 kinase; pNKCC1 = 374 
phosphorylated (active) NKCC1; TAK1 = Transforming growth factor beta-activated kinase; 375 
pTAK1= phosphorylated TAK1; pNa+/K+ ATPase = phosphorylated Na+/K+ ATPase; AQP1 = 376 
aquaporin-1. 377 
(B) Western Blot analysis of CPE ion transport mediators in TLR4 wild-type (TLR4 WT) 378 
animals and TLR4 knockout (TLR4 KO) animals 48 hours after experimental IVH (n=3). The 379 
blots in the figure have been cropped for presentation, please see supplemental information to 380 
view the uncropped blots. 381 
(C, D) Graphs representing the mean ± SEM of the β-Actin-normalized Western blot signal of 382 
the indicated antigen as depicted in triplicate columns 1, 2, 4 and 5 of panel (A). *, p < 0.05 vs. 383 
control; one-way ANOVA (n=3). 384 
(E) Graph representing the mean ± SEM of the ratio of the β-Actin-normalized Western blot 385 
signal of the indicated antigen as depicted in the third triplicate column of panel (A), 386 
demonstrating the effect of TAK242 treatment on CPE ion transport mediators 48 hours post 387 
experimental IVH. *, p < 0.05 vs. control; #, p < 0.01 vs. IVH but not vs. controls (p > 0.05); 388 
one-way ANOVA (n=3).  389 
(F) Graph representing the mean ± SEM of the β-Actin-normalized Western blot signal of the 390 
indicated antigen as depicted in (B), demonstrating lack of ion transporter up-regulation in TLR4 391 
KO animals. Graph contains a break from 2 to 7 on the Y-axis to accommodate elevated 392 
expression of pNKCC1 in the IVH condition.  393 
(G) Graph depicting CSF secretion rates (µL/min) 48 hours after experimental IVH, in TLR4 394 
WT untreated animals, in TLR4 WT animals treated with TAK242, and in TLR4 KO animals. 395 
  396 
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ONLINE METHODS 508 
 509 
Animals 510 
Animal experiments were performed under a protocol approved by the Institutional Animal Care 511 
and Use Committee (IACUC) of the University of Maryland, and in accordance with the 512 
guidelines and regulations in the NIH Guide for the Care and Use of Laboratory Animals. Male 513 
Wistar rats (Harlan, Indianapolis, IN, USA), or Tlr4-/- rats41 (bred in accordance with IACUC 514 
protocol at the University of Maryland, Baltimore), age 8 weeks (220-230g), were anesthetized 515 
(60 mg/kg ketamine plus 7.5 mg/kg xylazine, IP) and allowed to breathe room air spontaneously. 516 
Body temperature was maintained at 37 ± 1°C (Harvard Apparatus, Holliston, MA, USA) 517 
throughout the course of the experiments.  Animals in this study were randomly chosen for either 518 
control or experimental conditions, the researchers were not blinded, and no animals were 519 
excluded.  520 
 521 
Model of post-hemorrhagic hydrocephalus 522 
IVH was modeled using a modified protocol based on previously described methods.42,43  In an 523 
anesthetized animal, the tail artery was aseptically cannulated using a flexible catheter (PE-20) 524 
pre-loaded with heparinized saline. The rat was then mounted in a stereotactic apparatus 525 
(Stoelting Co., Wood Dale, IL), a midline scalp incision was made to expose the skull and a 1 526 
mm burr hole was made using a high-speed drill over the right lateral ventricle (coordinates, x= -527 
0.8, y= -1.7 mm relative to bregma). Approximately 200 µL of blood was then drawn from the 528 
tail artery catheter and loaded into a 500 µL syringe (Hamilton, Reno, NV), which was then 529 
mounted to the stereotactic frame. Under stereotactic guidance, 50 µL of freshly collected 530 
autologous blood, free from anticoagulants, was infused into the right lateral ventricle 531 
(coordinates, x= -0.8, y= -1.7, z= -4.5 mm relative to bregma), over the course of 5 minutes, and 532 
the 26-gauge needle was held in place for an additional 20 minutes to prevent backflow of blood 533 
upon needle removal. Intraventricular infusion of sterile aCSF (Tocris, Bristol, UK) in the same 534 
manner served as the control condition.  535 
 536 
Quantitation of rates of CSF production 537 
Rates of CSF production were measured using the method we recently published.44 Briefly, 538 
anesthetized rats were mounted in a stereotactic apparatus and a 1.3 mm burr hole was made 539 
over the left lateral ventricle (coordinates, x= -0.8, y= +1.7 relative to bregma). Next, the rat’s 540 
head was rotated on the ear-bars 90ᵒ, nose-down, and the suboccipital muscles were dissected to 541 
the cisterna magna to expose the atlanto-occipital ligament. The ligament was punctured and a 542 
23-gauge flexible catheter (PE-20) was advanced 5 mm through the foramen of Magendie to the 543 
4th ventricle. Sterile, molecular grade mineral oil (100 µL; Sigma Aldrich, St. Louis, MO) was 544 
infused into the 4th ventricle to occlude the aqueduct of Slyvius, thereby creating a closed 545 
system of CSF circulation. With the rat in the same position, a glass capillary tube (cat # 546 
CV8010-300; borosilicate; OD, 1 mm; ID, 0.8 mm; length, 30 cm; VitroCom, Mountain Lakes, 547 
NJ) was advanced through the burr hole into the left lateral ventricle. The volume (V) of CSF 548 
that formed at a given timepoint was calculated as: ܸ	ሺ݉݉ଷሻ = ߨ ∙ ݎଶ ∙ ݀, where r is the radius 549 
of the capillary tube and d is the distance CSF traveled within the capillary. The rate of CSF 550 
formation (µL/min) could be calculated from the slope of the volume–time relationship. 551 
 552 
Ventricular volume analysis 553 
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Following IP injection of pentobarbital, rats were transcardially perfused with ice-cold normal 554 
saline followed by 10% neutral buffered formalin. The brains were harvested, kept in formalin 555 
for 24 hours at 4°C and then cryoprotected (30% sucrose). To prevent distortion from 556 
cryosectioning and slide mounting, we took high resolution pictures of serial coronal sections 557 
(200 µm apart, 14 levels) while the brain was mounted in the cryostat, using uniform parameters 558 
of camera positioning, magnification, and external lighting. Adobe Photoshop was used to obtain 559 
a pixel count of the lateral ventricular area in each thick section. Pixels were converted to area in 560 
mm2, summed over 14 levels and multiplied by the distance between levels (0.2 mm) to calculate 561 
ventricular volume. 562 
 563 
8hr aCSF infusion 564 
In anesthetized naïve rats, a 28-gauge cannula from an Alzet brain infusion kit (#1; Durect, 565 
Cupertino, CA), with a single spacer to adjust the depth to 4.5 mm, was stereotactically placed in 566 
the burr hole over the right lateral ventricle and secured to the skull using cyanoacrylate 567 
adhesive. A solution of aCSF was infused at 1 µL/min over the course of 8 hours. At the end of 8 568 
hours, the rat was euthanized and transcardially perfused and processed for ventricular volume 569 
analysis as described above.   570 
 571 
Immunohistochemistry 572 
Rats were transcardially perfused with ice-cold normal saline followed by 10% neutral buffered 573 
fomalin. Brains were harvested and kept in formalin for 24 hours before being transferred to a 574 
30% sucrose solution for cryoprotection. Brains were cryosectioned (10µm, coronal), blocked 575 
(2% donkey serum, +0.2% Triton X-100 for 1 hour at RT) then incubated overnight at 4°C with 576 
primary antibodies. Sections were washed three times in phosphate-buffered saline and incubated 577 
for 1 hour at RT with secondary antibodies (1:500; Alexa Fluor 488 and Alexa Fluor 555; 578 
Invitrogen, Molecular Probes, Eugene, OR, USA). Sections were coverslipped using a polar 579 
mounting medium containing 4’6-diamidino-2-phenylindole (DAPI; Invitrogen, Eugene, OR, 580 
USA) and analyzed with epifluorescence microscopy (Nikon Eclipse 90i; Nikon Instruments 581 
Inc., Melville, NY, USA). Quantitation was performed by regions of interest (ROI) using NIS-582 
Elements AR software (Nikon Instruments Inc., Melville, NY, USA) and specific signal was 583 
defined as > 2 x background.  584 
 585 
Choroid plexus protein isolation and immunoprecipitation 586 
Buffers. Buffer A contained 50 mM Tris/HCl, pH7.5 and 0.1 mM EGTA. Lysis buffer was 50 587 
mM Tris/HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 5 mM sodium 588 
pyrophosphate, 1 mM sodium orthovanadate, 1% (w/v) NP-40, 0.27 M sucrose, 0.1% (v/v) 2-589 
mercaptoethanol and protease inhibitors (1 tablet per 50 ml). TBS-Tween buffer (TTBS) was 590 
Tris/HCl, pH 7.5, 0.15 M NaCl and 0.2% (v/v) Tween-20. SDS sample buffer was 1X-NuPAGE 591 
LDS sample buffer (Invitrogen), containing 1% (v/v) 2-mercaptoethanol.  592 
Isolation. Choroid plexuses were harvested rapidly from adult rat brains following transcardial 593 
perfusion with ice-cold saline. The brain was isolated and then placed in an ice-cold saline bath, 594 
after which the choroid plexus was carefully dissected under magnification using sharp forceps. 595 
Approximately 3 mg of choroid plexus tissue was harvested from one brain, which was then 596 
collected into a 1.5 mL tube.  597 
 598 
Immunoblotting and immunoprecipitation.  599 
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Clarified lysates of CP membrane fraction (15 µg) in SDS sample buffer were subjected to 600 
electrophoresis on polyacrylamide gels and transferred to nitrocellulose membranes. The 601 
membranes were incubated for 30 min with TTBS containing 5% (w/v) skim milk. The 602 
membranes were then immunoblotted in 5% (w/v) skim milk in TTBS with the indicated primary 603 
antibodies overnight at 4°C. Sheep antibodies were used at a concentration of 1-2 µg/ml. The 604 
incubation with phospho-specific sheep antibodies was performed in the presence of 10 µg/ml of 605 
the dephospho-peptide antigen to ensure phospho-antigen specificit. The blots were then washed 606 
six times with TTBS and incubated for 1 hour at room temperature with secondary HRP-607 
conjugated antibodies diluted 5000-fold in 5% (w/v) skim milk in TTBS. After repeating the 608 
washing steps, the signal was detected with enhanced chemiluminescence reagent. Immunoblots 609 
were developed using a film automatic processor (SRX-101; Konica Minolta Medical) and films 610 
were scanned with a 600-dpi resolution on a scanner (PowerLook 1000; UMAX). Figures were 611 
generated using Photoshop/Illustrator (Adobe). The relative intensities of immunoblot bands 612 
were determined by densitometry with ImageJ software. NKCC1 and SPAK were 613 
immunoprecipitated from the indicated cell extracts. 0.2 mg of the indicated clarified cell extract 614 
was incubated with 15 μg of the indicated antibody conjugated to 15 μl of protein-G–Sepharose. 615 
Incubation was for 2 hours at 4°C with gentle agitation, and the immunoprecipitates were 616 
washed three times with 1 ml of lysis buffer containing 0.15 M NaCl and twice with 1 ml of 617 
buffer A. Bound proteins were eluted with 1x lithium dodecyl sulfate (LDS) sample buffer (see 618 
"Antibodies for Western blot and immunoprecipitation" below for greater detail).  619 
 620 
ICV drug treatment 621 
The technique described previously for the administration of ICV drugs while measuring the rate 622 
of CSF secretion was used.44 Briefly, at the time of CSF collection, before rotating the head to a 623 
vertical orientation, a 28-gauge cannula from an Alzet brain infusion kit (#1; Durect, Cupertino, 624 
CA), with a single spacer to adjust the depth to 4.5 mm, was stereotactically placed in the burr 625 
hole over the right lateral ventricle and secured to the skull using cyanoacrylate adhesive. The 626 
cannula was connected via a preloaded PE-20 catheter to a 1 mL syringe containing the drug 627 
solution (see below). The syringe was loaded into a syringe infusion apparatus (Pump elite 11, 628 
Harvard Apparatus) and maintained at 37°C. To determine rate of CSF formation during 629 
intraventricular drug infusion, the “actual infusion rate” of the drug (1.93 µL/min) was 630 
subtracted from the “measured outflow rate” to obtain the operational “calculated rate of CSF 631 
formation”. To assess the effect of a drug, the baseline rate of CSF formation was determined 632 
during spontaneous CSF formation (no drug infusion), then the calculated rate of formation was 633 
determined after switching to the test drug. Percent change (Δ%) was determined using the 634 
formula: ߂% = ሺ௖௔௟௖௨௟௔௧௘ௗ	௥௔௧௘ሻିሺ௕௔௦௘௟௜௡௘	௥௔௧௘ሻ௕௔௦௘௟௜௡௘	௥௔௧௘ . Intraventricular infusion solutions were made 635 
using artificial CSF (aCSF), composed as follows (in mM): Na 150; K 3.0; Ca 1.4; Mg 0.8; P 636 
1.0; Cl 155, pH 7.19 (Tocris, Bristol, UK), with a calculated osmolarity of 311.2 mOsmC/L. The 637 
following drugs were used: acetazolamide (45 mM, pH 9; Sigma Aldrich, St. Louis, MO), 638 
STOCK-1S 50699 (100 µM, pH 6, 1% DMSO), Closantel (30 µM, pH 7.2, 0.1% DMSO; Sigma 639 
Aldrich) and Bumetanide (2.7 mM, pH 9; Sigma Aldrich). Due to differences in drug solubility, 640 
each drug had a specific vehicle control to account for pH, DMSO co-solvent, and osmolarity to 641 
ensure that these differences did not alter rate of CSF production. For each control solution, 642 
aCSF solution was altered using NaOH and HCl (Sigma Aldrich), to adjust pH, and mannitol 643 
(Sigma Aldrich), to adjust the osmolarity. In each case, the vehicle controls had no statistical 644 
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effect on the baseline rate of CSF and therefore, a representative vehicle control will be 645 
presented in data analysis for simplicity of data presentation.  646 
 647 
Systemic ammonium pyrrolidinedithiocarbamate (PDTC) administration 648 
PDTC (100mg/kg in normal saline, IP, Sigma Aldrich) was administered IP at the time of IVH 649 
surgery and every 8 hours thereafter until 48 hours post IVH. At 48 hours following IVH, rats 650 
were either (i) euthanized and transcardially perfused with saline and 10% neutral buffered 651 
formalin and processed for immunohistochemistry analysis, as described above, or (ii) 652 
anesthetized for surgery to allow measurement of the rate of CSF secretion, described above.  653 
 654 
Systemic bumetanide administration 655 
The efficacy of systemic bumetanide administration was determined by IV infusion of 656 
bumetanide at the time of measuring the rate of CSF production. In an anesthetized rat, the 657 
internal jugular vein was exposed and catheterized using a PE-20 flexible catheter preloaded 658 
with sterile normal saline. The rat was then mounted into a stereotactic frame in the normal 659 
manner for the CSF measurement analysis described above. A baseline measurement of the rate 660 
of CSF production was calculated for 25 minutes. After the baseline rate was determined, the 661 
saline-filled syringe attached to the jugular catheter was removed and replaced with a 662 
bumetanide-loaded syringe (1 mg/mL in pH 9 normal saline), and 1 mL was infused over 1 663 
minute. Following bumetanide infusion, CSF measurement was continued for an addition 30 664 
minutes to detect any changes in the rate of production. 665 
 666 
Systemic TAK-242 administration 667 
TAK-242 (ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate) 668 
was purchased from Sigma Aldrich. The concentration of TAK-242 chosen for intravenous 669 
administration (1mg/kg/hr; pH 7.2; 10% (2-Hydroxypropyl)-β-cyclo-dextrin in normal saline; 670 
0.5% DMSO) was based on previous studies demonstrating the half-life45 and efficacy of drug46-671 
48 at a concentration range of 0.5 – 1 mg/kg in rats. TAK-242 was dissolved in 100% DMSO for 672 
stock solutions and diluted with 10% (2-Hydroxypropyl)-β-cyclo-dextrin in normal saline (pre-673 
warmed to 37˚C) for working solutions to a final concentration of 0.5% DMSO. TAK-242 674 
solution was loaded into an Alzet osmotic pump (2ML1; Durect, Cupertino, CA). In an 675 
anesthetized rat, the internal jugular vein was exposed and catheterized using a PE-20 flexible 676 
catheter preloaded with the TAK-242 solution connected to the alzet pump. The catheter was 677 
secured into place, and the pump was implanted subcutaneously on the back. 5 days following 678 
TAK-242 pump implantation, the rats were anesthetized and subjected to the model of IVH as 679 
described above. The TAK-242 treatment continued over the next 48 hours at which point, the 680 
rat either underwent CSF secretion measurements or choroid plexus harvest for western blot 681 
analysis.  682 
 683 
In vivo knockdown of SPAK  684 
Previously validated SPAK antisense oligodeoxynucleotides (ODN; Integrated DNA 685 
Technologies, Coralville, IA) were used for in vivo knockdown of SPAK.49 ODNs were 686 
reconstituted in sterile normal saline and diluted to a final concentration of 0.5 µg/µL for ICV 687 
injection. All solutions were sterile-filtered. The rats were injected ICV under stereotactic 688 
guidance with a 10 µL bolus of either SPAK or scrambled ODN every 12h starting 24h prior to 689 
IVH and continued until 48hr following IVH. The sequences were as follows: SPAK, 690 
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GG*CTCC*GCC*ATG*ATGC*TGC; scrambled, CGC*TCG*ATCC*AGG*TCA*GCG (* 691 
denotes position of locked nucleic acids). To validate the ability of ODNs to knockdown SPAK, 692 
IHC was used to detect SPAK and pNKCC1 in naïve rats and in 24 hr IVH rats treated with 693 
either scrambled or anti-SPAK ODN.  694 
 695 
Antibodies for IHC 696 
The following primary antibodies were used: rabbit anti-SPAK (1:200; Cell Signaling 697 
Technology, Danvers, MA; Catalog #2281); rabbit anti-phosphorylated SPAK (pSPAK, Ser 373, 698 
1:200, EMD Millipore, Billerica, MA; Catalog #07-2273); rabbit anti-NKCC1 (1:200, Abcam, 699 
Cambridge, MA, Catalog #ab59791); rabbit anti-phosphorylated NKCC1 (pNKCC1, Thr 700 
212/Thr 217, 1:200, EMD Millipore; Catalog #ABS1004); rabbit anti-NFB/p65 (1:200, Santa 701 
Cruz, Dallas, TX; Catalog #sc-372); mouse anti-ED1 (1:100, EMD Millipore; Catalog 702 
#MAB1435); goat anti-TNFα (1:200, Santa Cruz; Catalog #sc-1350); goat anti-IBA1 (1:200, 703 
Abcam, Catalog #ab5076). Protein was detected using species-appropriate, fluorophor-labeled 704 
secondary antibodies (Cell Signaling Technology).  705 
 706 
Antibodies for Western blot and immunoprecipitation 707 
The following antibodies were raised in sheep and affinity-purified on the appropriate antigen by 708 
the Division of Signal Transduction Therapy Unit at the University of Dundee: NKCC1 total 709 
antibody [residues 1-288 of human NKCC1, Catalog S022D]; NKCC1 phospho-710 
Thr203/Thr207/Thr212 antibody [residues 198-217 of human NKCC1 phosphorylated at Thr203, 711 
Thr207 and Thr212, HYYYD(T)HTN(T)YYLR(T)FGHNT, Catalog S763B]; SPAK-mouse 712 
antibody [2–76 of mouse SPAK, Catalog S668D]; SPAK/OSR1 (S-motif) phospho-Ser373/Ser325 713 
antibody [367–379 of human SPAK, RRVPGS(S)GHLHKT, which is highly similar to residues 714 
319–331 of human OSR1 in which the sequence is RRVPGS(S)GRLHKT, Catalog S670B). β-715 
Actin (8H10D10) Mouse antibody, Phospho-NF-κB p65 (Ser536) antibody (Catalog #3031), 716 
NF-κB p65 (D14E12) antibody (Catalog #8242), Na+,K+-ATPase antibody (Catalog #3010) and 717 
phospho-Na+,K+-ATPase α1 (Ser23) antibody (Catalog #4006) were purchased from Cell 718 
Signaling Technology. TLR4 antibody (L-14) (Catalog sc-16240) and AQP1 antibody (Catalog 719 
sc-9878) were purchased from Santa Cruz Biotechnology, Inc.. NFκB p105 / p50 antibody 720 
(Catalog ab31412), TAK1 (phospho T187) antibody (Catalog ab192443) and TAK1 antibody 721 
(Catalog ab25879) were purchased from Abcam. Horseradish peroxidase-coupled secondary 722 
antibodies for immunoblotting were obtained from Pierce. SPAK and NKCC1 total antibodies 723 
and the phosphorylation site-specific antibodies were coupled with protein-G–Sepharose at a 724 
ratio of 1 mg of antibody per 1 mL of beads in the presence of 20 µg/mL of lysate to which the 725 
corresponding non-phosphorylated peptide had been added. 200 µg of clarified cell lysate were 726 
incubated with 10 µg of antibody conjugated to 10 µL of protein-G–Sepharose for 2 hours at 4°C 727 
with gentle agitation. Beads were washed three times with 1 mL of lysis buffer containing 0.15 728 
M NaCl and twice with 1 mL of wash buffer (50 mM Tris/HCl, pH7.5 and 0.1mM EGTA). 729 
Bound proteins were eluted with 1X LDS sample buffer (Invitrogen) containing 1% (v/v) 2-730 
mercaptoethanol. IgG used in control immunoprecipitation experiments was affinity-purified 731 
from pre-immune serum using Protein G-Sepharose. 732 
 733 
Data Analysis 734 
All statistics were completed in OriginPro (OriginLab Corporation, Northampton, MA) using 735 
one-way ANOVA analysis with a Tukey post-hoc test for differences between groups, two-736 
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sample t-test, or paired t-test. Statistical information including exact sample size, f-values, t-737 
valves, and degrees of freedom for all analyses are presented below organized by the 738 
corresponding figure. P-values less than 0.0001 are represented in scientific notation, e.g. 1E-04. 739 
Numerical data in text and figures are given as mean ± standard error of the mean (SE). Rates 740 
(µL/min) were calculated as the slope of the volume-time relationship, based on data collected 741 
over 30 min or more. Rates were determined for individual animals and were averaged across 742 
individuals. Sample size calculations were based on two previous studies that used the same 743 
model of IVH42 and the method for measuring rates of CSF production.44 Sample sizes were 744 
calculated using an a priori sample size calculator with the following assumptions: α=0.05; two-745 
tailed; desired power, 80%; anticipated effect size (Cohen’s d), 3. Calculations indicate that a 746 
minimum of 3 rats per group would be required. Statistical methods were reviewed and approved 747 
by the consultants at StatsLab at Yale University School of Medicine.  748 
 749 
Figure 1B: Sample sizes: CTL n=12; 24hr IVH n=3; 48hr IVH n=13; 72hr IVH n=3; 7d IVH 750 
n=3.  751 
One-way ANOVA: F-value = 30.53; degrees of freedom (df) = 33. P-values: 24hr IVH vs. CTL 752 
= 1.50E-07; 48hr IVH vs. CTL = 2.51E-08; 72hr IVH vs. CTL = 2.22E-04; 7d IVH vs. CTL = 753 
0.015. Figure 1D: Sample sizes: Naive (N), Vehicle control (CTL), IVH: n=3; aCSF n=5. One-754 
way ANOVA: F-value = 14.43; df = 13. P-values: CTL vs. Naïve = 0.86; IVH vs. CTL = 0.007; 755 
aCSF vs. CTL = 0.01; aCSF vs. IVH = 0.85. Figure 1E: Sample sizes: CTL n=12; IVH n=13; 756 
IVH + PDTC n=3. One-way ANOVA: F-valve = 48.78; df = 27. P-values: IVH vs. CTL = 0; 757 
IVH + PDTC vs. CTL = 0.16; IVH + PDTC vs. IVH = 8.35E-04. Sample sizes: IVH + Vehicle 758 
n=3; IVH + ACZ n=3; IVH + BUM n=3. One-way ANOVA: F-value = 40.66; df = 8. P-values: 759 
ACZ vs. Veh = 0.21; BUM vs. Veh = 3.35E-04; BUM vs. ACZ = 0.001. Figure 1F: Sample size: 760 
n=3. Paired T-test; Two-tailed: T-value = -1.11; df = 2. P-value: 0.38 Figure 1G: Sample size: 761 
48hr IVH n=5. Paired T-test; two-tailed: T-value = 12.79; df = 4. P-value: 2.15E-04. Sample 762 
size: 7d IVH n=3. Paired T-test; two-tailed: T-value = 12.79; df = 3. P-value: 0.02 763 
 764 
Figure 2B: Sample size n=3 all conditions. Two sample T-test; two-tailed; df = 4: all conditions.  765 
pSPAK: T-value = -7.49, P-value = 0.0017; SPAK: T-value = -0.36; P-value = 0.74. pNKCC1: 766 
T-value = -16.01, P-value = 8.90E-05; NKCC1: T-value = -0.59; P-value = 0.59. pOSR1: T-767 
value = -5.98, P-value = 0.004; pNa+/K- ATPase: T-value = 17.67, P-value = 6.02E-05. Na+/K- 768 
ATPase: T-value = 11.83, P-value = 2.92E-04; AQP1: T-value = 5.35, P-value = 0.006. Figure 769 
2F: Sample sizes: CTL n=4; IVH n=4; IVH + PDTC n=3. One-way ANOVA: pSPAK: F-value = 770 
14.80; df = 10. pNKCC1: F-value = 15.07; df = 10. P-values: pSPAK: IVH vs. CTL = 0.012; 771 
IVH + PDTC vs. CTL = 0.26; IVH + PDTC vs. IVH = 0.002. pNKCC1: IVH vs. CTL = 0.002; 772 
IVH + PDTC vs. CTL = 0.13; IVH + PDTC vs. IVH = 0.049. Figure 2G: Sample sizes: CTL = 773 
12; IVH + Scr = 5; IVH + AS = 5. One-way ANOVA: F-value = 19.98; df = 21. P-values: IVH + 774 
Scr vs. CTL = 1.39E-05; IVH + AS vs. CTL = 0.44; IVH + AS vs. IVH + Scr = 0.0012. Sample 775 
sizes: Veh, STK, Clos n=3 all conditions. One-way ANOVA: F-value = 38.66; df = 8. P-values: 776 
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IVH + Veh vs. IVH + STK = 0.0015; IVH + Clos vs. IVH + Veh = 3.83E-04; IVH + Clos vs. 777 
IVH + STK = 0.21. Figure 2I: Sample sizes: CTL n=3; IVH n=3; IVH + BUM n=4; IVH + 778 
PDTC n=3; IVH + Clos n=3. One-way ANOVA: F-value = 12.21; df = 15. P-values: IVH vs. 779 
CTL = 0.0011; IVH + BUM vs. CTL = 1; IVH + BUM vs. IVH = 6.70E-04; IVH + PDTC vs. 780 
CTL = 1; IVH + PDTC vs. IVH = 0.0011; IVH + Clos vs. CTL = 0.74; IVH + Clos vs. IVH = 781 
0.007. 782 
 783 
Figure 3C: Sample sizes: n=3 all conditions. One-way ANOVA: pSPAK: F-value = 53.04; df = 784 
11; P-values: 24hr IVH vs. CTL = 1.52E-05; 48hr IVH vs. CTL = 3.99E-05; 7d IVH vs. CTL = 785 
0.004. pNKCC1: F-value = 23.85; df = 11; P-values: 24hr IVH vs. CTL = 2.91E-04; 48hr IVH 786 
vs. CTL = 6.11E-04; 7d IVH vs. CTL = 0.022. NFκB: F-value = 21.36; df = 11; P-values: 24hr 787 
IVH vs. CTL = 4.10E-04; 48hr IVH vs. CTL = 0.003; 7d IVH vs. CTL = 0.27. AQP1: F-value = 788 
16.9; df = 11; P-values: 24hr IVH vs. CTL = .033; 48hr IVH vs. CTL = .1; 7d IVH vs. CTL = 789 
0.056. Figure 3D: Sample sizes: n=3 all conditions. One-way ANOVA: pTAK: F-value = 9.60; 790 
df = 11; P-values: 24hr IVH vs. CTL = .0067; 48hr IVH vs. CTL = .045; 7d IVH vs. CTL = 0.88. 791 
TAK: F-value = 1.92; df = 11; P-values: 24hr IVH vs. CTL = 0.99; 48hr IVH vs. CTL = 0.20; 7d 792 
IVH vs. CTL = 0.63. pNa+/K- ATPase: F-value = 5.80; df = 11; P-values: 24hr IVH vs. CTL = 793 
0.019; 48hr IVH vs. CTL = 0.080; 7d IVH vs. CTL = 0.49. Na+/K- ATPase: F-value = 5.52; df = 794 
11; P-values: 24hr IVH vs. CTL = 0.23; 48hr IVH vs. CTL = 0.11; 7d IVH vs. CTL = 0.69. 795 
Figure 3E: Sample sizes: n=3 all conditions. One-way ANOVA: pSPAK: F-value = 207.98; df = 796 
11; P-values: IVH vs. CTL = 4.03E-06; TAK242 + IVH vs. CTL = 0.30; TAK242 + IVH vs. 797 
IVH = 7.12E-06. pNKCC1: F-value = 89.48; df = 11; P-values: IVH vs. CTL = 6.72E-05; 798 
TAK242 + IVH vs. CTL = 0.94; TAK242 + IVH vs. IVH = 5.65E-05. pTAK: F-value =14.58; df 799 
= 11; P-values: IVH vs. CTL = 0.017; TAK242 + IVH vs. CTL = 0.51; TAK242 + IVH vs. IVH 800 
= 5.07E-03. NFκB: F-value = 20.05; df = 11; P-values: IVH vs. CTL = 0.0023; TAK242 + IVH 801 
vs. CTL = 0.044; TAK242 + IVH vs. IVH = 0.0079. AQP1: F-value = 3.51; df = 11; P-values: 802 
IVH vs. CTL = 0.27; TAK242 + IVH vs. CTL = 0.089; TAK242 + IVH vs. IVH = 0.67. Figure 803 
3F: Sample sizes: n=3 all conditions. One-way ANOVA: pSPAK: F-value = 40.09; df = 11; P-804 
values: IVH vs. CTL = 6.69E-04; TLRKO + IVH vs. CTL = 0.94; TLRKO + IVH vs. IVH = 805 
5.29E-04. pNKCC1: F-value = 52.05; df = 11; P-values: IVH vs. CTL = 3.14E-04; TLRKO + 806 
IVH vs. CTL = 0.96; TLRKO + IVH vs. IVH = 2.63E-04; pTAK: F-value = 95.75; df = 11; P-807 
values: IVH vs. CTL = 5.34E-05; TLRKO + IVH vs. CTL = 0.97; TLRKO + IVH vs. IVH = 808 
4.79E-05. NFκB: F-value = 10.34; df = 11; P-values: IVH vs. CTL = .022; TLRKO + IVH vs. 809 
CTL = 0.94; TLRKO + IVH vs. IVH = 0.015; AQP1: F-value = 31.92; df = 11; P-values: IVH 810 
vs. CTL = 0.0017; TLRKO + IVH vs. CTL = 7.99E-04; TLRKO + IVH vs. IVH = 6.41E-01. 811 
Figure 3G: Sample sizes: CTL n=12; IVH n=3; TAK242 + IVH n=3; TLRKO + IVH n=3. One-812 
way ANOVA: F-value = 15.30; df = 20. P-values: IVH vs. CTL = 3.31E-05; TAK242 + IVH vs. 813 
CTL 0.67; TAK242 + IVH vs. IVH = 0.003; TLRKO + IVH vs. CTL 0.87; TLRKO + IVH vs. 814 
IVH = 1.42E-04. 815 
 816 
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Supplemental Figure 1D: p65: Sample sizes: CTL n=3; IVH n=4; IVH + PDTC n=5. One-way 817 
ANOVA: F-value = 89.78; df = 11. P-values: IVH vs. CTL = 4.27E-06; IVH + PDTC vs. CTL = 818 
0.90; IVH + PDTC vs. IVH = 1.95E-06. ED1: Sample sizes: n=3 all conditions.   819 
One-way ANOVA: F-value = 92.37; df = 8. P-values: IVH vs. CTL = 3.93E-05; IVH + PDTC 820 
vs. CTL = 0.29; IVH + PDTC vs. IVH = 8.96E-05. 821 
 822 
Supplemental Figure 2B: Sample sizes: CTL n=5; 48hr IVH n=5; 7d IVH n=6; all conditions. 823 
One-way ANOVA: pSPAK: F-value = 42.46; df = 15; P-values: 48hr IVH vs. CTL = 0.001; 7d 824 
IVH vs. CTL = 1.20E-06. pNKCC1: F-value = 8.25; df = 15; P-values: 48hr IVH vs. CTL = 825 
0.047; 7d IVH vs. CTL = 0.004. p65: F-value = 46.81; df = 15; P-values: 48hr IVH vs. CTL = 826 
6.35E-05; 7d IVH vs. CTL = 7.93E-07. TNFα: F-value = 8.05; df = 15; P-values: 48hr IVH vs. 827 
CTL = 0.016; 7d IVH vs. CTL = 0.007. IBA1: F-value = 4.71; df = 15; P-values: 48hr IVH vs. 828 
CTL = 0.032; 7d IVH vs. CTL = 0.072. ED1: F-value = 6.42; df = 15; P-values: 48hr IVH vs. 829 
CTL = 0.067; 7d IVH vs. CTL = 0.01. 830 
 831 
 832 
 833 
 834 
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